U060 The Gray Zones in High Risk CSCC
DESCRIPTION
High risk cutaneous squamous cell carcinoma often presents challenging management decisions where evidence is limited and consensus is lacking. This session will focus on the “gray zones” of CSCC management through practical, case based discussions addressing topics such as imaging, nodal evaluation, adjuvant radiation, systemic therapy, immunosuppression, and management of medically complex patients. Emphasis will be placed on real world decision making, areas of controversy, and individualized patient care.
LEARNING OBJECTIVES
Navigate the “gray zones” of high risk CSCC by applying practical decision making strategies to complex real world cases.
Identify areas of controversy and uncertainty in CSCC management, including imaging, radiation, nodal evaluation, and systemic therapy.
Integrate patient, tumor, and treatment factors to individualize management of high risk and medically complex CSCC patients.
SCHEDULE
8:00 AM
"Who is really high risk?" Staging, calculators, GEP, and ctDNA
Kathryn Shahwan, MD, FAAD
8:12 AM
Nodal evaluation: imaging, SLNB, or watch?
Sean Christensen, MD, PhD, FAAD
8:24 AM
Radiation Therapy: who benefits?
Nina Ran, MD, MS, FAAD
8:36 AM
Perioperative systemic therapy: neoadjuvant and adjuvant approaches
David R. Carr, MD, MPH, FAAD
8:48 AM
Q&A Period
DIRECTOR
David R. Carr, MD, MPH, FAAD
The Ohio State University
CO-DIRECTOR
Kathryn Shahwan, MD, FAAD
SPEAKERS
Sean Christensen, MD, PhD, FAAD
Yale University School of Medicine
Nina Ran, MD, MS, FAAD
DISCLOSURES
David R. Carr, MD, MPH, FAAD
Regeneron – Investigator(No Compensation Received); Sun Pharmaceutical Industries Ltd. – Advisory Board(Honoraria);
Sean Christensen, MD, PhD, FAAD
inhibitor therapeutics – Advisory Board(Fees); Natera – Advisory Board(Honoraria); Regeneron Pharmaceuticals Inc – Advisory Board(Honoraria); Sol-Gel Technologies – Investigator(Grants/Research Funding); Sun Pharmaceutical Industries Ltd. – Advisory Board(Honoraria);
Nina Ran, MD, MS, FAAD
Chronicle Medical Software – Consultant (1099 relationship)(Fees);
Kathryn Shahwan, MD, FAAD
Highlight Therapeutics – Advisory Board(Honoraria); Sun Pharmaceutical – Advisory Board(Honoraria);